Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma
The Journal of Pathology: Clinical Research · 2026-03 · 12 (2)
DOI: 10.1002/2056-4538.70083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 16.03.2026. Verfasst von Deema Sabtan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Charite, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin,…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Immunoconjugates, Carcinoma, Pancreatic Ductal, Cell Adhesion Molecules. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Else Kröner-Fresenius-Stiftung, Berlin Institute of Health, Clinician Scientist Program.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody–drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial heterogeneity (six cores per patients) of three ADC targets (c‐MET, NECTIN4, and TROP‐2) in a cohort of 62 PDAC patients (1,116 tissue cores) and associate their levels with clinicopathological and genomic parameters, and the expression of immune checkpoints. c‐MET exhibited significantly higher expression at the tumor front versus tumor center, along with notable intratumoral heterogeneity. In contrast, NECTIN4 and TROP‐2 displayed homogeneous expression patterns, with NECTIN4 being absent in approximately two‐thirds of cases, while TROP‐2 showed consistently strong positivity across tumor regions (98% 3+). By simulating sampling sufficiency for reliable scoring, we observed that, for c‐MET, two tumor samples were sufficient to achieve a maximum score of 1+, while for higher scores (2+ and 3+), four samples were required. For NECTIN4, four samples were necessary to detect scores of 1+ and 2+. For TROP‐2, for a 3+ score, just two samples were sufficient to reach the maximum score. c‐MET or TROP‐2 expression scores were not associated with any clinicopathological parameters. In contrast, NECTIN4 expression showed an association with tumor grade. Correlations with immune checkpoints revealed that high TROP‐2 expression was inversely correlated with PD‐L1 expression. For all three markers no significant differences in expression were found between SMAD4 wild‐type and SMAD4 ‐mutated tumors, nor between TP53 wild‐type and TP53 ‐mutated tumors. Furthermore, analysis of lymph node and distant (liver and peritoneal) metastases revealed significantly higher c‐MET and NECTIN4 expression in the metastatic setting. In conclusion, TROP‐2 is highly expressed in most PDACs, independent of clinicopathological and genomic parameters, and inversely correlating with PD‐L1, making TROP‐2 an ideal ADC target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Charite, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
- Department of Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Berlin, Heidelberg, Germany.
- Berlin Institute of Health, Charite, Universitätsmedizin Berlin, Berlin, Germany.
- Institute of Pathology, Ludwig Maximilians University, Munich, Germany.
- Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Munich Partner Site, Heidelberg, Germany.
ORCID-Profile: Mihnea P Dragomir
Förderung
- Bundesministerium für Bildung und Forschung
- Else Kröner-Fresenius-Stiftung
- Berlin Institute of Health, Clinician Scientist Program
- DKTK Berlin Young Investigator Grant 2022
- Charite University Medicine Berlin
- Bundesministerium für Forschung, Technologie und Raumfahrt
- Berlin Institute of Health
Zitieren
APA
Sabtan, D., Eich, M. L., Loch, F., Pérez Zuschneid, J. K., Möbs, M., Böhme, J., Klauschen, F., Horst, D., Dragomir, M. P., Dernbach, G., & Schallenberg, S. (2026). Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma. The Journal of Pathology: Clinical Research, 12(2). https://doi.org/10.1002/2056-4538.70083
Vancouver
Sabtan D, Eich ML, Loch F, Pérez Zuschneid JK, Möbs M, Böhme J, et al. Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma. The Journal of Pathology: Clinical Research. 2026;12(2). doi:10.1002/2056-4538.70083
BibTeX
@article{Sabtan2026,
author = {Sabtan, Deema and Eich, Marie-Lisa and Loch, Florian and Pérez Zuschneid, Julen Karl and Möbs, Markus and Böhme, Judith and Klauschen, Frederick and Horst, David and Dragomir, Mihnea P and Dernbach, Gabriel and Schallenberg, Simon},
title = {Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {2},
doi = {10.1002/2056-4538.70083}
}
EUVIMED